Compare Global X NASDAQ 100 Covered Call ETF (QYLD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X NASDAQ 100 Covered Call ETF vs TG Therapeutics Inc — how do they compare? Global X NASDAQ 100 Covered Call ETF trades at $17.82, while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Global X NASDAQ 100 Covered Call ETF nearer its low. Which is the better fit depends on your goals.
| QYLD | TGTX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $18.52 | $59.06 |
52-Week Low | $16.46 | $26.39 |
Market Cap | — | $8.26B |
Enterprise Value | — | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QYLD trades at $17.66, down 0.84% with a bearish technical outlook. The ETF shows neutral oscillators but bearish moving averages, with RSI at oversold levels. Recent dividend payments of $0.18-$0.19 highlight its income focus, though news articles question long-term wealth erosion versus Nasdaq growth.
The outlook remains cautious due to covered-call strategy limitations during market rallies. Risks include NAV erosion and underperformance versus benchmarks. Income-focused investors may find value, but growth-oriented investors face significant upside capture constraints in bullish markets.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
